title: Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels.
abstract: Tissue factor pathway inhibitor (TFPI) is a naturally occurring, Kunitz-type serine protease inhibitor whose anticoagulant activity is due to an inhibition of the extrinsic coagulation pathway. Heparin injection has previously been shown to increase the plasma levels of TFPI. In this study, plasma samples were obtained from a multiple dose phase I tolerance study with a synthetic analogue of heparin, namely Aprosulate (PALLAS). Volunteers were randomized into four treatment groups: (A) 35 mg Aprosulate b.i.d. s.c.; (B) 70 mg Aprosulate b.i.d. s.c.; (C) 70 mg Aprosulate o.d. + placebo o.d. s.c.; (D) 40 mg of a low molecular weight heparin, Enoxaparin o.d. + placebo o.d. s.c. All treatments were for 7 days, with blood samples taken periodically over this time period. TFPI antigen levels were determined using Imubind TFPI ELISA kits (American Diagnostica, Greenwich, CT). TFPI antigen levels were observed to rapidly increase to levels two- to three-fold over baseline in all groups. Aprosulate caused a slightly larger increase in TFPI antigen levels than Enoxaparin, though this may be related to the doses chosen for this study. These data indicate that plasma concentrations of TFPI are increased following Aprosulate administration. TFPI may be important in mediating the antithrombotic activity of Aprosulate.
authors.affiliation: Department of Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA.
authors.forename: W
authors.initials: W
authors.lastname: Jeske
authors.forename: D
authors.initials: D
authors.lastname: Hoppensteadt
authors.forename: R
authors.initials: R
authors.lastname: Klauser
authors.forename: A
authors.initials: A
authors.lastname: Kammereit
authors.forename: P
authors.initials: P
authors.lastname: Eckenberger
authors.forename: S
authors.initials: S
authors.lastname: Haas
authors.forename: P
authors.initials: P
authors.lastname: Wyld
authors.forename: J
authors.initials: J
authors.lastname: Fareed
mesh_terms: D000704:Analysis of Variance; D000925:Anticoagulants / Q000494:pharmacology*; D000941:Antigens / Q000097:blood*; D004187:Disaccharides / Q000494:pharmacology*; D004334:Drug Administration Schedule; D017984:Enoxaparin / Q000494:pharmacology*; D006801:Humans; D008074:Lipoproteins / Q000276:immunology*; D008297:Male; D012016:Reference Values; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*
chemical_list: D000925:Anticoagulants; D000941:Antigens; D004187:Disaccharides; D017984:Enoxaparin; D008074:Lipoproteins; D015842:Serine Proteinase Inhibitors; C051928:lipoprotein-associated coagulation inhibitor; C069690:aprosulate